NCT03578432 is a EARLY_PHASE1 clinical trial of Everolimus in Salivary Gland Dysfunction, sponsored by University of Arizona.

Who is sponsoring NCT03578432?

NCT03578432 is sponsored by University of Arizona.

What drugs are being tested in NCT03578432?

Interventions in NCT03578432: Everolimus, Laboratory Biomarker Analysis, Survey Administration.

What condition does NCT03578432 study?

NCT03578432 studies Salivary Gland Dysfunction, Xerostomia, Head and Neck Cancer.

Is NCT03578432 still recruiting?

NCT03578432 is currently terminated. Last updated 2 December 2019.

Last reviewed 2019-12-02 · How we verify

NCT03578432

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy

Terminated EARLY_PHASE1 Last updated 2 December 2019

What this trial tests

EARLY_PHASE1 trial testing Everolimus in Salivary Gland Dysfunction in 2 participants. Terminated before completion.

Timeline

4 May 2018

Primary endpoint
15 November 2019

15 November 2019

Quick facts

Lead sponsor	University of Arizona
Phase	EARLY_PHASE1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	2
Start date	4 May 2018
Primary completion	15 November 2019
Estimated completion	15 November 2019
Sites	1 location across United States

Drugs / interventions tested

Everolimus (everolimus) — full drug profile →
Laboratory Biomarker Analysis — full drug profile →
Survey Administration

Conditions studied

Salivary Gland Dysfunction — all drugs for Salivary Gland Dysfunction →
Xerostomia — all drugs for Xerostomia →
Head and Neck Cancer — all drugs for Head and Neck Cancer →

Sponsor

University of Arizona

Who can join

Adults 18 to 75, any sex, with Salivary Gland Dysfunction or Xerostomia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This early phase 1 trial studies the use of everolimus in restoring salivary gland function in participants with locally advanced head and neck cancer after concurrent chemoradiation or radiation therapy alone.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

mTOR inhibitor use in head and neck squamous cell carcinoma: A meta-analysis on survival, tumor response, and toxicity.
Patel J, Nguyen SA, Ogretmen B, Gutkind JS, et al · · 2020 · cited 19× · PMID 32337356 · DOI 10.1002/lio2.370
The Role of the PI3K/Akt/mTOR Axis in Head and Neck Squamous Cell Carcinoma.
Jiang Q, Xiao J, Hsieh YC, Kumar NL, et al · · 2024 · cited 18× · PMID 39062182 · DOI 10.3390/biomedicines12071610

Verify or expand the search:

Other trials of Everolimus

Trials testing the same drug.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07318324 — Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer · Phase 1 · not yet recruiting
NCT07477548 — A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies · Phase 2 · not yet recruiting
NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT06832189 — EVR and EPO for Liver Transplant Tolerance · Phase 1 · recruiting

Other University of Arizona trials

Trials by the same sponsor.

NCT04062890 — Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance · Phase 2 · withdrawn
NCT05569486 — Elucidating the Central Mechanisms of Action for Green Light Therapy in Managing Chronic Pain · NA · not yet recruiting
NCT05064111 — Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy · suspended
NCT06567899 — Mechanistic Underpinnings of Preeclampsia · not yet recruiting
NCT07254793 — Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03578432 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Arizona
Last refreshed: 2 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03578432.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing